CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Neurosense Therapeutics Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Neurosense Therapeutics Ltd
11 Hamenofim St.
Phone: +972 97996183p:+972 97996183 HERZLIYA, 4672562  Israel Ticker: NRSNNRSN
Business Summary
NeuroSense Therapeutics Ltd. is an Israel-based clinical-stage pharmaceutical company engaged in the development of therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The Company’s lead product candidate, PrimeC, is an oral fixed-dose combination therapy designed for the treatment of ALS. In addition to PrimeC, the Company conducts research and development activities focused on neurodegenerative disorders, including Alzheimer’s disease and Parkinson’s disease. The Company develops pharmaceutical products and therapeutic solutions aimed at addressing unmet medical needs in neurological diseases and related central nervous system disorders. The Company also advances therapies for rare neurological conditions.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202512/31/2025YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Non-Executive Chairman of the Board Mark W.Leuchtenberger 10/1/2021 10/1/2021
Chief Executive Officer, Director AlonBen-Noon 42 2/1/2017 2/1/2017
Chief Financial Officer OrEisenberg 40 6/1/2021 6/1/2021
5 additional Officers and Directors records available in full report.

Business Names
Business Name
NeuroSense GmbH
NeuroSense US Inc.
NRSN

General Information
Number of Employees: 16 (As of 12/31/2025)
Outstanding Shares: 44,528,923 (As of 7/31/2026)
Shareholders: 1,343
Stock Exchange: NASD


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, August 15, 2026